CEP

Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Risk, Broad, Esophageal cancer, Medicare, Physician, Centers for Medicare & Medicaid Services, CEP, Prognosis, Pharma, Securities Exchange Act of 1934, Borrowing base, EBITDA, Security (finance), Center, Diagnosis, Pancreatic cyst, COVID-19, Company, Drug development, Private Securities Litigation Reform Act, Novita (company), Safety, U.S. Securities and Exchange Commission, Pancreatic cancer, Review, National Correct Coding Initiative, Thyroid cancer, Terminology, LCD, NCCI, Franciscan Ceramics, Lung cancer, Cancer, Securities Act of 1933, OTCQX, Patient, Technology, Personal Data Privacy and Security Act of 2009, Sumathi Best Television Current Reporting Award, Comerica, Goal, CEO, CMS, Health, Policy, Health insurance

As a result, the Company will continue billing for both tests according to its Laboratory Coverage Determination (LCD) as originally set by Novitas.

Key Points: 
  • As a result, the Company will continue billing for both tests according to its Laboratory Coverage Determination (LCD) as originally set by Novitas.
  • According to CMS, this updated policy will be posted on its website and will be included in the July 1, 2022 edit file.
  • Tom Burnell, Interpaces President and CEO stated, We appreciate the prompt consideration of our appeal by NCCI and CMS to prevent any beneficiary access issues for our Medicare covered thyroid testing.
  • We believe this is the correct policy based on the patient management for thyroid patients to allow physicians to help improve care and treatment of their patients.

Clairvest Reports Fiscal 2022 Third Quarter Results

Retrieved on: 
Thursday, February 10, 2022
Income, CEP, Toronto Stock Exchange, CEO, Company, GLOBE, Sale, Acquisition, CVG, Knowledge, TSX, Industry, Video game, Security (finance)

TORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX: CVG) today reported results for the fiscal 2022 third quarter and nine months ended December 31, 2021 and material events subsequent to quarter end.

Key Points: 
  • TORONTO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Clairvest Group Inc. (TSX: CVG) today reported results for the fiscal 2022 third quarter and nine months ended December 31, 2021 and material events subsequent to quarter end.
  • During the quarter, the Company purchased and cancelled 6,000 common shares which was accretive to the book value per share.
  • As at December 31, 2021, Clairvests investment in AlsoEnergy was carried at approximately the sale proceeds received subsequent to quarter end.
  • Our third quarter was a busy quarter for the Clairvest team.

Special San Onofre Community Engagement Panel Meeting to Focus on Department of Energy Initiative for Off-Site Spent Nuclear Fuel Storage

Retrieved on: 
Thursday, February 3, 2022
Public Policy, Government, State, Local, Other Consumer, Consumer, Utilities, Energy, Nuclear, CEP, Retirement, Safety, YouTube, Nuclear Energy Institute, Marine Corps Base Camp Pendleton, Nuclear energy, Second VA-35 (U.S. Navy), Central, Twitter, Navy, Â, Microsoft, Population, DOE, Dry cask storage, Coast, Edison International, Blue Ribbon Commission on America's Nuclear Future, RFI, Department, Blue-ribbon committee, NYSE, Southern California Edison, SCE, Primary energy, Renewable energy, Facebook

The meeting will begin at noon Pacific Time, to accommodate East Coast participants, and take place via Microsoft Teams video conference.

Key Points: 
  • The meeting will begin at noon Pacific Time, to accommodate East Coast participants, and take place via Microsoft Teams video conference.
  • By prioritizing communities and people, we believe we can find a solution to the decades-long stalemate on managing the nations spent nuclear fuel.
  • There are 123 canisters of spent nuclear fuel safely stored at San Onofre, which is located on land leased from the U.S. Navy as part of Marine Corps Base Camp Pendleton.
  • Until the spent fuel is removed, decommissioning cannot be fully completed and the land restored for return to the Navy.

Uberflip Named a WordPress VIP Technology Partner

Retrieved on: 
Thursday, February 3, 2022
Growth, CEP, CEO, FiveThirtyEight, News Corp, View, Content, Dow Jones, CMS, Friction, Capgemini, Technology, WordPress, Marketing, Partnership, Rolling Stone, Thought, VIP, Hachette Book Group, Forrester Research, Multimedia, Solution, Nightclub, Facebook, Merck, Quartz

"WordPress VIP is experiencing significant growth and our partners are key players in our success powering exceptional digital experiences at scale for marketers," said WordPress VIP CEO Nick Gernert.

Key Points: 
  • "WordPress VIP is experiencing significant growth and our partners are key players in our success powering exceptional digital experiences at scale for marketers," said WordPress VIP CEO Nick Gernert.
  • "We're excited to welcome Uberflip to our partner community to help us deliver best-in-class products for enterprise WordPress users."
  • As the experts in enterprise WordPress, WordPress VIP provides a fully managed WordPress cloud platform for unparalleled scale, security, performance, and flexibility, as well as end-to-end guidance and hands-on support.
  • "We are thrilled to partner with WordPress VIP," says Yoav Schwartz, CEO of Uberflip.

University of Phoenix College of Nursing Receives NEPIN Quality Designation

Retrieved on: 
Wednesday, February 2, 2022
Health, Continuing, University, Nursing, Education, CCNE, CEP, Faculty, Michelle McMurry-Heath, Patient, Academy, Education, Nursing school, University, Interest, COA, Caregiver, RWJF, Decision-making, Moral and National Education controversy, Commission, Phoenix College, ACEN, Accrediting Commission for Education in Nursing, Student, Careers New Zealand, Health, Commission on Collegiate Nursing Education, University of Phoenix, APIN, CNEA, Suite, ACME, RN, Florida State University College of Nursing, Pediatric Leadership Alliance, Medicine, Nursing, Accreditation, College, NW

University of Phoenix College of Nursing is being recognized as the inaugural recipient of the National Education Progression in Nursing (NEPIN) Quality Designation.

Key Points: 
  • University of Phoenix College of Nursing is being recognized as the inaugural recipient of the National Education Progression in Nursing (NEPIN) Quality Designation.
  • The Universitys College of Nursing accredited programs prepare students for the delivery of quality, compassionate care.
  • University of Phoenix College of Nursing has demonstrated their commitment to this purpose by earning this designation.
  • The College of Nursing recognizes that flexible and relevant educational programs are essential to prepare students for contemporary nursing practice.

Infinite Equity Announces the Hiring of Terry Adamson

Retrieved on: 
Tuesday, February 1, 2022
Consulting, Professional Services, Human Resources, Finance, CEP, Professional, Leadership, TSR, Relative, Society of Actuaries, Goal, VWAP, Society, ESG, Technology, Infinite, Creative industries, Equity

Infinite Equity , a premier independent professional services firm that enables companies to increase the effectiveness and return of their equity programs, today announced Terry Adamson has joined its senior leadership team.

Key Points: 
  • Infinite Equity , a premier independent professional services firm that enables companies to increase the effectiveness and return of their equity programs, today announced Terry Adamson has joined its senior leadership team.
  • Terry is a well-known visionary in the equity compensation field and has been widely recognized for his leadership.
  • Terry will focus on business development, expanding partnerships, and continuing his proven track-record of bringing fresh ideas to equity compensation.
  • Infinite Equity is known for its success in assisting companies to increase the effectiveness and return of their equity programs, believing that equity compensation drives performance and fuels success.

Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests

Retrieved on: 
Saturday, January 29, 2022
Diagnosis, CEP, Broad, CEO, Safety, Private Securities Litigation Reform Act, Risk, CMS, Health, Policy, Physician, Goal, Technology, Centers for Medicare & Medicaid Services, Securities Act of 1933, Center, Medicare, COVID-19, Cancer, Pharma, Pancreatic cancer, U.S. Securities and Exchange Commission, Franciscan Ceramics, Company, Lung cancer, GLOBE, Esophageal cancer, EBITDA, Pancreatic cyst, Prognosis, Drug development, Securities Exchange Act of 1934, Comerica, Security (finance), Thyroid cancer, Terminology, Sumathi Best Television Current Reporting Award, OTCQX, Pharmaceutical industry, Risk management

The CMS change does not in any way impact the efficacy of the diagnostic information provided to clinicians.

Key Points: 
  • The CMS change does not in any way impact the efficacy of the diagnostic information provided to clinicians.
  • We will continue to evaluate the impact of the change in the CMS policy and potential changes on the Companys operations and will keep our stockholders informed.
  • Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

Retrieved on: 
Thursday, January 27, 2022
U.S. Securities and Exchange Commission, Board of directors, Physician, Comerica, Diversified Pharmaceutical Services, Securities Exchange Act of 1934, Lung cancer, Sumathi Best Television Current Reporting Award, Security (finance), Managed care, Diagnosis, GlaxoSmithKline, GLOBE, Growth, Esophageal cancer, Private Securities Litigation Reform Act, MEGA Cosmos (Ethnic Channels Group), Cancer, Pancreatic cancer, Safety, EBITDA, Health, Broad, Board, Hotel manager, Technology, Securities Act of 1933, Company, Drug development, Thyroid cancer, Franciscan Ceramics, CEP, CEO, OTCQX, Colorectal cancer, Pharma, Prognosis, COVID-19, Pancreatic cyst, Investment, Risk, Terminology, Goal, Pharmaceutical industry, Laboratory

PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (Interpace) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022.

Key Points: 
  • PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (Interpace) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022.
  • Dr. Aggarwal replaces Eric B. Lev, both designees of Ampersand 2018 Limited Partnership, a Series B Preferred stockholder of the Company.
  • We are very excited to welcome Dr. Aggarwal to our Board of Directors, stated Thomas Burnell, President and CEO of Interpace.
  • Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries.

Uberflip Announces New Features & Capabilities Designed to Elevate User Experience

Retrieved on: 
Tuesday, January 25, 2022
Calendar, Multimedia, CEP, VP, Time, Software, Friction, Marketing, PDF, SDR, Mobile phone, Video game console

TORONTO, Jan. 25, 2022 /PRNewswire/ -- Uberflip , the leading cloud-based content experience platform (CEP), today announces its most recent product releases.

Key Points: 
  • TORONTO, Jan. 25, 2022 /PRNewswire/ -- Uberflip , the leading cloud-based content experience platform (CEP), today announces its most recent product releases.
  • All of this functionality aligns with the company's chief priority of improving the user experience.
  • "Uberflip is valuable in my day-to-day when sending outreach," said Brian O'Connell, SDR at TripleLift, of Sales Assist.
  • To learn more about Uberflip and these notable new capabilities, or to schedule a demo, click here .

Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering

Retrieved on: 
Wednesday, January 12, 2022
Securities Exchange Act of 1934, Technology, Form S-1, Exercise, Private Securities Litigation Reform Act, SEC, Franciscan Ceramics, COVID-19, Safety, Securities Act of 1933, Eastern Time Zone, Esophageal cancer, Thyroid cancer, GLOBE, Pharma, Pancreatic cancer, Health, Investor, Ownership, Pancreatic cyst, Industry, Goal, Sumathi Best Television Current Reporting Award, Prognosis, Company, Diagnosis, Drug development, Date, Form, SEC filing, CEP, Risk, Cancer, Rights, Sale, Lung cancer, Prospectus, Physician, Terminology, Security (finance)

PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Interpace or the Company) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million.

Key Points: 
  • PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Interpace or the Company) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped Rights Offering of up to $30 million.
  • The rights will expire if they are not exercised by 5:00 p.m., Eastern Standard Time, on February 2, 2022, unless the Company extends the Rights Offering subscription period.
  • Holders who fully exercise their rights may subscribe for additional shares not subscribed for by other holders on a pro rata basis.
  • For any questions or further information about the rights offering, please call Broadridge Corporate Solutions, Inc., the Companys information and subscription agent for the Rights Offering, at (888) 789-8409.